Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 4/20 | 0.44 |
| ▸ | PIEZO1 | Q92508 | 13/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15599488 | 0.77 | KDM4E (0.50) | KDM4ETERTPIEZO1HSD17B10MEN1 | |
| SCHEMBL8629789 | 0.73 | KDM4E (0.50) | KDM4EHSD17B10ALDH1A1MAPT | |
| SCHEMBL16997502 | 0.73 | KDM4E (0.47) | KDM4ETERTPIEZO1HSD17B10MEN1 | |
| SCHEMBL19984983 | 0.73 | KDM4E (0.47) | KDM4ETERTPIEZO1HSD17B10MEN1 | |
| SCHEMBL26671383 | 0.73 | KDM4E (0.47) | KDM4ETERTPIEZO1HSD17B10MEN1 | |
| SCHEMBL8830039 | 0.72 | KDM4E (0.49) | KDM4EHSD17B10ALDH1A1MAPT | |
| SCHEMBL10563043 | 0.70 | TERT (0.56) | KDM4ETERTPIEZO1HSD17B10MEN1 | |
| SCHEMBL26777790 | 0.70 | KDM4E (0.48) | KDM4ETERTPIEZO1HSD17B10MEN1 | |
| SCHEMBL29454745 | 0.68 | NISCH (0.50) | KDM4EALDH1A1 | |
| SCHEMBL29598957 | 0.68 | NISCH (0.50) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005037239-A2 | USE OF A COMPOUND FROM THE GROUP OF HETERODIAZOLES OR A SALT OF SAID COMPOUND, COSMETIC OR THERAPEUTIC FORMULATION CONTAINING SAID COMPOUND OR SALT, SAID COMPOUND OR SALT AS A THERAPEUTIC AGENT, AND SAID SALT | SYMRISE GMBH & CO. KG (DE) | 2005-04-28 | — | — | WO | claimed |
| US-4861367-A | 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles or 2-mercapto-5-pyrazinyl-1,3,4-thiadiazoles as nematicides | CIBA-GEIGY CORPORATION (US) | 1989-08-29 | — | — | US | claimed |
| EP-0290379-A2 | 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles and -1,3,4-thiadiazoles, process for their preparation and their use as nematicidal agents | CIBA-GEIGY AG (CH) | 1988-11-09 | — | — | EP | claimed |
| EP-4103144-B1 | COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026087745-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732825-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4110277-B1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | SYMRISE AG (DE) | 2026-04-09 | — | — | US | disclosed |
| EP-3045161-B1 | Use of active mixtures of 1,2-hexanediol and 1,2-octanediol in cosmetic, pharmaceutical or dermatological emulsions | SYMRISE AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4025675-B1 | A PERFUME OIL MIXTURE | SYMRISE AG (DE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4706780-A2 | COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS | Symrise AG (DE) | 2026-03-11 | — | — | EP | disclosed |
| EP-0859767-B1 | FLUOROPROPENYL OXADIAZOLES AND THE USE THEREOF AS PEST CONTROL AGENTS | BAYER AG (DE) | 2000-10-11 | — | — | EP | disclosed |
| US-4861367-A | 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles or 2-mercapto-5-pyrazinyl-1,3,4-thiadiazoles as nematicides | CIBA-GEIGY CORPORATION (US) | 1989-08-29 | — | — | US | disclosed |
| US-4861367-A | 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles or 2-mercapto-5-pyrazinyl-1,3,4-thiadiazoles as nematicides | CIBA-GEIGY CORPORATION (US) | 1989-08-29 | — | — | US | disclosed |
| US-4861367-A | 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles or 2-mercapto-5-pyrazinyl-1,3,4-thiadiazoles as nematicides | CIBA-GEIGY CORPORATION (US) | 1989-08-29 | — | — | US | disclosed |
| EP-0290379-A3 | 2-MERCAPTO-5-PYRAZINYL-1,3,4-OXADIAZOLES AND -1,3,4-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS NEMATICIDAL AGENTS | CIBA-GEIGY AG (CH) | 1989-02-22 | — | — | EP | disclosed |
| EP-0290379-A3 | 2-MERCAPTO-5-PYRAZINYL-1,3,4-OXADIAZOLES AND -1,3,4-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS NEMATICIDAL AGENTS | CIBA-GEIGY AG (CH) | 1989-02-22 | — | — | EP | disclosed |
| EP-0290379-A2 | 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles and -1,3,4-thiadiazoles, process for their preparation and their use as nematicidal agents | CIBA-GEIGY AG (CH) | 1988-11-09 | — | — | EP | disclosed |
| EP-0290379-A2 | 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles and -1,3,4-thiadiazoles, process for their preparation and their use as nematicidal agents | CIBA-GEIGY AG (CH) | 1988-11-09 | — | — | EP | disclosed |
| EP-0290379-A2 | 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles and -1,3,4-thiadiazoles, process for their preparation and their use as nematicidal agents | CIBA-GEIGY AG (CH) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | PTGS2, PTGES2, PTGS1 | KDM4E 4565/4885TERT 633/4885PIEZO1 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.